President Donald Trump after signing the 'One Big Beautiful Bill' on the South Lawn at the White House (Yuri Gripas/Abaca/Sipa USA/Sipa via AP Images)

July 7, 2025 03:14 PM EDT

Law

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Zachary Brennan

Senior Editor

President Donald Trump on July 4 signed into law his wide-ranging tax cuts and reconciliation package, including an expansion of orphan drug protections from Medicare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

The Supreme Court passed on a state PBM case. Lawyers say a broad­er le­gal fight is brew­ing

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases